Quick Answer
Metagenomi Therapeutics, Inc. reported Net Income of -$87.87 million for fiscal year 2025.
Metagenomi Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$87.87M | -12.6% |
| 2024 | -$78.06M | -14.4% |
| 2023 | -$68.25M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$20.39M | -8.6% | -2.4% |
| June 30, 2025 | -$19.91M | -85.4% | +20.5% |
| March 31, 2025 | -$25.04M | +0.4% | -33.4% |
| September 30, 2024 | -$18.77M | +5.3% | -74.8% |
| June 30, 2024 | -$10.74M | +17.4% | +57.3% |
| March 31, 2024 | -$25.15M | -55.9% | -26.9% |
| September 30, 2023 | -$19.82M | — | -52.4% |
| June 30, 2023 | -$13.01M | — | +19.4% |
- Metagenomi Therapeutics, Inc. showed a decrease of -12.6% in Net Income compared to the prior fiscal year.
- Over the 2023–2025 period, Metagenomi Therapeutics, Inc.’s net income has declined by 28.7% (from -$68.25 million to -$87.87 million).
- The most recent figure is from Metagenomi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: